2018 Stanford Drug Discovery Conference

April 23-24, 2018
Li Ka Shing Conference Center

Shark Tank Application

Now accepting applications for translational stage projects to be presented to a panel of  leading scientists, CEOs, and entrepreneurs

Advances in research and technology now afford us the unique opportunity to develop and test novel diagnostics and therapeutics. This conference takes advantage of the collective experience and expertise of our speakers in drug discovery. A broad range of policy, research, and venture topics are covered.


Howard Bauchner, MD
Editor in Chief, JAMA

Paul Berg, PhD
Robert W. And Vivian K. Cahill Professor of Cancer Research, Emeritus

Robert Bradway
CEO, Amgen

Amy Chang
CEO, Accompany

Edward Engleman, MD
Professor of Pathology and Medicine (Immunology and Rheumatology)

Ken Frazier
CEO, Merck


Kathleen Giacomini, PhD
Professor, Co-Director UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation

Gary Gibbons, MD
Director, NHLBI


Joe Jimenez
Former CEO, Novartis

John Keaney, MD
Associate Editor, NEJM

Paula Kiberstis, PhD
Senior Editor, Science

Brian Kobilka, MD
Helene Irwin Fagan Chair in Cardiology, Stanford

Maria Millan, MD
President and CEO, CIRM


Lloyd Minor, MD
Carl and Elizabeth Naumann Professorship for the Dean of the School of Medicine | Professor of Otolaryngology—Head & Neck Surgery

Joao Monteiro, MD, PhD
Chief Editor
Nature Medicine


Robert Robbins, MD
President, University of Arizona


Hugh Rosen, MD, PhD
Scripps Institute
ActiveX Biosciences

Brent Saunders
CEO, Allergan


George Scangos, PhD
CEO & Director, VIR


Kevan Shokat, PhD
Prof and Chair, Dept of Cellular and Molecular Pharmacology, UCSF | Prof, Dept of Chemistry, UC Berkeley

Ram Shriram
Founder & Managing Partner, Sherpalo Ventures

Patrick Soon-Shiong, MD
Chair of NantWorks, LLC, Executive Director of Wireless Health Institute at UCLA

Marc Tessier-Lavigne, PhD, FRS, FRSC
President and Bing Presidential Professor

Roy Vagelos, MD
Former Chariman and CEO, Merck & Co.


Sanford Weill
Chairman Emeritus of Citigroup and Philanthropist

Janet Woodcock, MD
Director, Center for Drug Evaluation and Research, FDA


Day 1 | April 23, 2018

Welcoming Remarks and Introduction

Joseph Wu, MD, PhD | Director, Stanford Cardiovascular Institute

Lloyd Minor, MD | Dean, Stanford School of Medicine

David Entwistle | CEO, Stanford Health Care

Chris Dawes | President and CEO, Lucille Packard Children’s Hospital Stanford

Opening Keynote

Brian Kobilka, MD | "Structure-based Approaches for G Protein Coupled Receptor Drug Discovery"

Q & A Session

Academic Drug Discovery Process

Session Chairs and Moderators: Janet Woodcock, MD, and Joseph Wu, MD, PhD

Kathleen Giacomini, PhD

Kevan Shokat, PhD | "Chemical Tricks for Drugging the Undruggable"

Hugh Rosen, MD, PhD | "Intelligent Intervention: Ozanimod from Hit to NCE at Scripps"

Edward Engleman, MD | "Treating Disease by Manipulating the Immune System"

Panel Discussion

View From the Top

Ken Frazier | "Inventing for Life: the CEO Perspective"

Joe Jimenez | "Outcomes Based Pricing"

Patrick Soon-Shiong, MD | "First in Human Innate NK Cell with Adaptive T Cell Immunotherapy in Patients with Solid Tumors"

Bob Bradway | "Moving from 'Break/Fix' to 'Predict/Prevent'"

Brent Saunders | "Using the Innovation Ecosystem to Build a Robust Pipeline"

Sanford Weill | "Philanthropy's Vital Role in Partnering with Healthcare"

Panel Discussion

Fireside Chat

Marc Tessier-Lavigne, FRS, FRSC, FMedSci

Lloyd Minor, MD

Q & A Session

Presentation of Lifetime Achievement Award to Roy Vagelos, MD

Introduction: Paul Berg, PhD, and Ken Frazier

Awardee Lecture: Roy Vagelos, MD | "A Career in Drug Discovery"

Day 2 | April 24, 2018

Funding Agency Perspectives

Session Chair and Moderator: Joseph Wu, MD, PhD

Gary Gibbons, MD | "Charting Our Future Together: Advancing Discovery Science for Public Health Impact"

Maria Millan, MD

Q & A Session

Publishing Drug Discovery

Howard Bauchner, MD | "Evolving Issues in Medical Journalism"

John Keaney, MD | "Editorial Considerations in the Evaluation of New Therapies"

Paula Kiberstis, PhD | "Drug Discovery and Science: What's behind the Curtain?"

Joao Monteiro, MD, PhD | "Transparency and Reproducibility in Science: How Journals Can Help"

Round Table Discussion

Starting Up

George Scangos, PhD | "Transitioning from Big Pharma to Startup"

Shark Tank-style Panel featuring:

Roy Vagelos, MD
George Scangos, PhD
Ram Shriram
Robert Robbins, MD
Amy Chang

Closing Keynote

Kuldev Singh, MD | Introduction

Janet Woodcock, MD | "Changes on the Horizon for the New Drug Regulatory Program"

Q & A Session

Closing Remarks / Poster Prize Award Announcement


Joseph C. Wu, MD, PhD

Director, Stanford Cardiovascular Institute

Simon H. Stertzer, MD, Professor
Department of Medicine (Cardiology) & Radiology

Sanjay V. Malhotra, PhD

Associate Professor (Research) of Radiation Oncology (Radiation and Cancer Biology) and of Radiology (Molecular Imaging Program at Stanford)

Mark Mercola, PhD

Professor of Medicine (Cardiovascular)

Chaitan Khosla, PhD

Wells H. Rauser and Harold M. Petiprin Professor in the School of Engineering and Professor of Chemistry and, by Courtesy, of Biochemistry

Kuldev Singh, MD

Professor of Ophthalmology at the Stanford University Medical Center

Katy Claiborn, PhD

Grants Writer, Cardiovascular Institute Operations

Supported by

Participation by

Amgen • Cytokinetics • Merck • Shang Pharma

Organizations interested in participating can contact Katy Claiborn.